Skip to content
The Nexus
DossierENTITY

orforglipron

Coverage of orforglipron in the Nexus archive.

Earliest in view: May 12 · 23:06 UTCMost recent: Aug 11 · 12:20 UTC
Co-mentioned in this coverage
United Kingdomplace2type 2 diabetestopic2glycemic controltopic2Eli Lillyorganization1Europetopic1weight managementtopic1Foundayotopic1ACHIEVE-5 trialtopic1American Diabetes Associationorganization1basal insulintopic1body weighttopic1ACHIEVE-5 trialorganization1insulin glarginetopic1MedPage Todayorganization1USplace1UKplace1
Recent coverage
  • HEALTHAug 11 · 12:20 UTCQUARTZ
    Eli Lilly's weight-loss pill is approved in the U.K.

    The U.K. regulator has approved orforglipron for weight management and type 2 diabetes. This approval makes Britain the first country in Europe to clear the drug.

  • HEALTHJul 6 · 16:45 UTCMEDPAGE TODAY
    Oral GLP-1 Drug May Simplify Diabetes Treatment

    The ACHIEVE-5 trial demonstrated that adding oral orforglipron (Foundayo) to basal insulin improved glycemic control and reduced body weight in diabetes patients. The results were presented at the American Diabetes Association annual meeting.

  • HEALTHJun 7 · 20:15 UTCMEDPAGE TODAY
    Add-On Orforglipron: Good News for Type 2 Diabetes and Inadequate Glycemic Control

    Once-daily orforglipron improved outcomes in adults with type 2 diabetes and inadequate glycemic control, according to the ACHIEVE-5 trial. The drug is an add-on treatment for patients already on insulin glargine.

  • HEALTHMay 12 · 23:06 UTCBBC HEALTH
    Daily pill to help keep weight off after stopping obesity jabs

    A daily pill called orforglipron is available in the US to help keep weight off after stopping obesity injections and may soon launch in the UK. The tablet aims to assist with weight management. This new treatment option could have a significant impact on obesity care.